DIGITAL BIOTECHNOLOGIES, INC.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
DIGITAL BIOTECHNOLOGIES, INC. - overview
Established
2021
Location
Seattle, WA, US
Primary Industry
Biotechnology
About
Digital Biotechnologies Inc. is a Seattle, US, based subsidiary of Adaptive Biotechnologies, a publicly traded immune medicine company. The firm develops next generation DNA sequencing technologies positioned adjacent to Adaptive’s core focus on immune medicine and Minimal Residual Disease (MRD) testing. In December 2025, Digital Biotechnologies raised USD 12.
27 million series A funding. Digital Biotechnologies is engineering a solid state clinical sequencing instrument aimed at overcoming limitations of current next generation sequencing platforms, which often struggle with accuracy, turnaround time, and affordability. The technology is being developed in collaboration with academic and industry scientists across the U. S.
and is designed for broad clinical applicability.
Primary Industry
Biotechnology
Sub Industries
Biotechnology
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.